Teva- Pharmaceutical Industries Ltd. ADR [TEVA] stock prices are up 0.18% to $28.46 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TEVA shares have gain 5.84% over the last week, with a monthly amount glided 15.69%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] stock has seen the most recent analyst activity on December 05, 2025, when Scotiabank initiated its Sector Outperform rating and assigned the stock a price target of $35. Previously, Goldman started tracking the stock with Buy rating on June 06, 2025, and set its price target to $24. On May 28, 2025, Truist initiated with a Buy rating and assigned a price target of $25 on the stock. JP Morgan upgraded its rating to an Overweight but stick to its price target of $23 on May 12, 2025. Argus upgraded its rating to a Buy but $20 remained the price target by the analyst firm on July 10, 2024. JP Morgan upgraded its rating to Neutral for this stock on March 08, 2024, but kept the price target unchanged to $14. In a note dated February 12, 2024, Piper Sandler upgraded an Overweight rating on this stock and boosted its target price from $12 to $19.
The stock price of Teva- Pharmaceutical Industries Ltd. ADR [TEVA] has been fluctuating between $12.47 and $28.46 over the past year. Currently, Wall Street analysts expect the stock to reach $31.5 within the next 12 months. Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] shares were valued at $28.46 at the most recent close of the market. An investor can expect a potential return of 10.68% based on the average TEVA price forecast.
Analyzing the TEVA fundamentals
The Teva- Pharmaceutical Industries Ltd. ADR [NYSE:TEVA] reported sales of 16.86B for trailing twelve months, representing a surge of 3.17%. Gross Profit Margin for this corporation currently stands at 0.5% with Operating Profit Margin at 0.05%, Pretax Profit Margin comes in at -0.0%, and Net Profit Margin reading is -0.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.0, Equity is -0.03 and Total Capital is 0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.57.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 28.08 points at the first support level, and at 27.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 28.76, and for the 2nd resistance point, it is at 29.06.
Ratios To Look Out For
It’s worth pointing out that Teva- Pharmaceutical Industries Ltd. ADR [NYSE:TEVA]’s Current Ratio is 1.11. In addition, the Quick Ratio stands at 0.82 and the Cash Ratio stands at 0.18. Considering the valuation of this stock, the price to sales ratio is 1.94, the price to book ratio is 4.50 and price to earnings (TTM) ratio is 46.48.
Transactions by insiders
Recent insider trading involved MIGNONE ROBERTO, Director, that happened on Nov 26 ’25 when 50000.0 shares were sold. Shareholder, Bridger Management, LLC (1) completed a deal on Nov 26 ’25 to buy 50000.0 shares. Meanwhile, EVP, Head of U.S. Commercial Fox Christine sold 28229.0 shares on Nov 20 ’25.
